Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A randomised, open-label, multicentre, phase 3 trial

The Lancet

Volumn 387, Issue 10028, 2016, Pages 1629-1637

  Schöffski, Patrick ^a   Chawla, Sant ^b   Maki, Robert G ^c   Italiano, Antoine ^d   Gelderblom, Hans ^e   Choy, Edwin ^f   Grignani, Giovanni ^g   Camargo, Veridiana ^h   Bauer, Sebastian ⁱ   Rha, Sun Young ^j   Blay, Jean Yves ^k   Hohenberger, Peter ^l   D'Adamo, David ^m   Guo, Matthew ^m   Chmielowski, Bartosz ⁿ   Le Cesne, Axel ^o   Demetri, George D ^p   Patel, Shreyaskumar R ^q  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Sarcoma Oncology Center   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d INSTITUT BERGONIÉ   (France)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g CANDIOLO CANCER INSTITUTE   (Italy)

^h HOSPITAL SÍRIO LIBANÊS   (Brazil)

ⁱ UNIVERSITY HOSPITAL ESSEN   (Germany)

^j Yonsei University College of Medicine   (South Korea)

^k UNIVERSITÉ LYON 1   (France)

^l UNIVERSITY OF HEIDELBERG   (Germany)

^m EISAI INC   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o INSTITUT GUSTAVE ROUSSY   (France)

^p HARVARD MEDICAL SCHOOL   (United States)

^q UNIVERSITY OF TEXAS   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERIBULIN; GEMCITABINE; IFOSFAMIDE; PAZOPANIB; TRABECTEDIN; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; FURAN DERIVATIVE; KETONE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ASTHENIA; BACKACHE; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER GRADING; CANCER SURVIVAL; CANCER THERAPY; CONFERENCE PAPER; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; HYPOKALEMIA; INTENTION TO TREAT ANALYSIS; LEIOMYOSARCOMA; LEUKOPENIA; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SOFT TISSUE SARCOMA; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; URINARY TRACT INFECTION; VOMITING; CLINICAL TRIAL; COMPARATIVE STUDY; MIDDLE AGED; PATHOLOGY; SECONDARY; SOFT TISSUE NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; FEMALE; FURANS; HUMANS; KETONES; LEIOMYOSARCOMA; LIPOSARCOMA; MALE; MIDDLE AGED; NEOPLASM GRADING; SOFT TISSUE NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84963668055     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)01283-0     Document Type: Conference Paper

References (27)

1. CD Fletcher, JA Bridge, P Hogendoorn, F Mertens WHO classification of tumours of soft tissue and bone 4th edn. 2013 World Health Organization
2. National Comprehensive Cancer Network clinical practice guidelines in oncology (NCCN guidelines) Soft tissue sarcoma. Version 1 2015 National Comprehensive Cancer Network Fort Washington, PA
3. P Schöffski, J Cornillie, A Wozniak, H Li, D Hompes Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease Oncol Res Treat 37 2014 355 362
4. G Mastrangelo, JM Coindre, F Ducimetière et al. Incidence of soft tissue sarcoma and beyond: a population-based prospective study in 3 European regions Cancer 118 2012 5339 5348
5. CA Stiller, A Trama, D Serraino et al. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project Eur J Cancer 49 2013 684 695
6. EA Nedea, TF DeLaney Sarcoma and skin radiation oncology Hematol Oncol Clin North Am 20 2006 401 429
7. RG Maki, JK Wathen, SR Patel et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 J Clin Oncol 25 2007 2755 2763
8. RR Munhoz, SP D'Angelo, MM Gounder et al. A Phase Ib/II study of gemcitabine and docetaxel in combination with pazopanib for the neoadjuvant treatment of soft tissue sarcomas Oncologist 20 2015 1245 1246
9. MA Dickson, DR D'Adamo, ML Keohan et al. Phase II trial of gemcitabine and docetaxel with bevacizumab in soft tissue sarcoma Sarcoma 2015 2015 532478
10. X García-Del-Muro, A López-Pousa, J Maurel et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study J Clin Oncol 29 2011 2528 2533
11. ESMO/European Sarcoma Network Working Group Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 25 suppl 3 2014 iii102 iii112
12. NF Dybdal-Hargreaves, AL Risinger, SL Mooberry Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent Clin Cancer Res 21 2015 2445 2452
13. JA Smith, L Wilson, O Azarenko et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability Biochemistry 49 2010 1331 1337
14. Y Funahashi, K Okamoto, Y Adachi et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models Cancer Sci 105 2014 1334 1342
15. T Yoshida, Y Ozawa, T Kimura et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states Br J Cancer 110 2014 1497 1505
16. E7389 administered as an IV bolus infusion day 1 and day 8 every 3 weeks in pre-treated patients with advanced and/or metastatic soft tissue sarcoma (NCT00413192). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00413192 (accessed July 22, 2015).
17. P Schöffski, IL Ray-Coquard, A Cioffi et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes Lancet Oncol 12 2011 1045 1052
18. EA Eisenhauer, P Therasse, J Bogaerts et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
19. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 2009 U.S. Department of Health and Human Services, National Institutes of Health, and National Cancer Institute https://www.acrin.org/portals/0/administration/regulatory/CTCAE-4.02-2009-09-15-quickreference-5x7.pdf (accessed July 22, 2015).
20. GD Demetri, M von Mehren, RL Jones et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial J Clin Oncol 2015; Sep 14 10.1200/JCO.2015.62.4734
21. L Paz-Ares, A López-Pousa, A Poveda et al. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone Invest New Drugs 30 2012 729 740
22. WT van der Graaf, JY Blay, SP Chawla et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial Lancet 379 2012 1879 1886
23. J Cortes, J O'Shaughnessy, D Loesch et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study Lancet 377 2011 914 923
24. PA Kaufman, A Awada, C Twelves et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane J Clin Oncol 33 2015 594 601
25. JY Blay, Z Papai, AW Tolcher et al. Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Oncol 16 2015 531 540
26. I Judson, J Verweij, H Gelderblom et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial Lancet Oncol 15 2014 415 423
27. RD Issels, LH Lindner, J Verweij et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study Lancet Oncol 11 2010 561 570